Peijia Medical commented on the acquisition of JenaValve Technology, Inc. ("JenaValve"), an exclusive technology licensing partner of Peijia, by Edwards Lifesciences ("Edwards") on July 24, 2024. As a result of the proposed acquisition, Peijia Medical would maintain the exclusive license for the JenaValve Trilogy™ Transcatheter Heart Valve (THV) System in Greater China. 

The acquisition of the product by industry giant Edwards Lifesciences will enhance global physicians' awareness of aortic regurgitation (AR) disease and accelerate the development of the JenaValve Trilogy™ THV system. After the transaction is closed, Peijia Medical will join forces with Edwards Lifesciences to commit to providing the latest and best procedural solutions for patients with AR in their respective global markets.